Novo Nordisk, Inc. is a major pharmaceutical company that develops and sells medicines, including drugs for diabetes and obesity. Its filings show it lobbies Congress on health care issues such as drug pricing, coverage for anti‑obesity medications, Medicare and Medicaid rules, and policies on compounding and counterfeit drugs. It also monitors tax rules for multinational companies and international trade talks.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
BRETT BAKER
The latest disclosures for this client.
THE NICKLES GROUP, LLC
Q4THE NICKLES GROUP, LLC
Q3The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THE NICKLES GROUP, LLC
GREG D'ANGELO
THE NICKLES GROUP, LLC
JEFF CHOUDHRY
THE NICKLES GROUP, LLC
MARY BETH SAVARY TAYLOR
THE NICKLES GROUP, LLC
RACHEL JONES HENSLER
THE NICKLES GROUP, LLC
MOLLY FROMM
THE NICKLES GROUP, LLC
mr LUKE HOLLAND
THE NICKLES GROUP, LLC
NICOLE WRIGHT
THE NICKLES GROUP, LLC
THE NICKLES GROUP, LLC
Q2THE NICKLES GROUP, LLC
Q1THE NICKLES GROUP, LLC
RR